CD274 and gastric cancer: In KEYNOTE-059, pembrolizumab exhibited favorable efficacy in gastric cancer, especially in PD-L1-positive patients, with an objective response rate (ORR) of 15.5% and duration of response (DOR) of 16.3 months (2).